CN111918868A - 作为蛋白激酶调节剂的二芳基大环化合物 - Google Patents

作为蛋白激酶调节剂的二芳基大环化合物 Download PDF

Info

Publication number
CN111918868A
CN111918868A CN201980025145.8A CN201980025145A CN111918868A CN 111918868 A CN111918868 A CN 111918868A CN 201980025145 A CN201980025145 A CN 201980025145A CN 111918868 A CN111918868 A CN 111918868A
Authority
CN
China
Prior art keywords
alkyl
reaction
compound
added
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980025145.8A
Other languages
English (en)
Other versions
CN111918868B (zh
Inventor
张寅生
高勇
赵大敏
王承启
徐宏江
施伟
贺香依
赵凯迪
尤心怡
王晓金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN111918868A publication Critical patent/CN111918868A/zh
Application granted granted Critical
Publication of CN111918868B publication Critical patent/CN111918868B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种作为蛋白激酶调节剂的二芳基大环化合物，具体而言，涉及式I化合物或其药学上可接受的盐、制备方法、含有该化合物的药物组合物，以及其在治疗癌症、疼痛、神经疾病、自体免疫疾病及炎症中的用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201980025145.8A 2018-05-04 2019-04-30 作为蛋白激酶调节剂的二芳基大环化合物 Active CN111918868B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810421414 2018-05-04
CN201810421414X 2018-05-04
CN2019101983296 2019-03-15
CN201910198329 2019-03-15
PCT/CN2019/085090 WO2019210835A1 (zh) 2018-05-04 2019-04-30 作为蛋白激酶调节剂的二芳基大环化合物

Publications (2)

Publication Number Publication Date
CN111918868A true CN111918868A (zh) 2020-11-10
CN111918868B CN111918868B (zh) 2022-12-30

Family

ID=68386965

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980025145.8A Active CN111918868B (zh) 2018-05-04 2019-04-30 作为蛋白激酶调节剂的二芳基大环化合物

Country Status (2)

Country Link
CN (1) CN111918868B (zh)
WO (1) WO2019210835A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021042890A1 (zh) * 2019-09-04 2021-03-11 罗欣药业(上海)有限公司 杂环化合物及其作为Trk激酶抑制剂的应用
AU2020402942B2 (en) * 2019-12-13 2023-05-11 Scinnohub Pharmaceutical Co., Ltd Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof
CN113045587A (zh) * 2019-12-27 2021-06-29 成都倍特药业股份有限公司 一种大环结构化合物的晶型及其制备方法
CN113045575B (zh) * 2019-12-27 2022-06-17 成都倍特药业股份有限公司 一种化合物的制备方法及其中间体和中间体的制备方法
CN113121568A (zh) * 2019-12-31 2021-07-16 成都倍特药业股份有限公司 一种大环结构化合物的盐及其制备方法
CN113563341B (zh) * 2020-04-29 2022-07-12 山东轩硕医药科技有限公司 作为Trk抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
CN114073704B (zh) * 2020-08-14 2023-08-11 赛诺哈勃药业（成都）有限公司 具有大环结构的含氟并杂环衍生物的应用
WO2022218276A1 (zh) * 2021-04-12 2022-10-20 成都倍特药业股份有限公司 含氟大环结构化合物的固体形态、制备方法和应用
CN117586277A (zh) * 2022-08-09 2024-02-23 苏州朗睿生物医药有限公司 一种大环三氮唑衍生物及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN104169286A (zh) * 2012-03-06 2014-11-26 辉瑞大药厂 用于治疗增殖性疾病的大环衍生物
CN106170289A (zh) * 2014-01-24 2016-11-30 Tp生物医药公司 作为蛋白质激酶的调节剂的二芳基巨环
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CN107735399A (zh) * 2015-07-02 2018-02-23 Tp生物医药公司 作为蛋白质激酶的调节剂的手性二芳基大环

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102971322A (zh) * 2010-05-20 2013-03-13 阵列生物制药公司 作为trk激酶抑制剂的大环化合物
CN104169286A (zh) * 2012-03-06 2014-11-26 辉瑞大药厂 用于治疗增殖性疾病的大环衍生物
CN106170289A (zh) * 2014-01-24 2016-11-30 Tp生物医药公司 作为蛋白质激酶的调节剂的二芳基巨环
CN107735399A (zh) * 2015-07-02 2018-02-23 Tp生物医药公司 作为蛋白质激酶的调节剂的手性二芳基大环
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof

Also Published As

Publication number Publication date
WO2019210835A1 (zh) 2019-11-07
CN111918868B (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
CN111918868A (zh) 作为蛋白激酶调节剂的二芳基大环化合物
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN107735399B (zh) 作为蛋白质激酶的调节剂的手性二芳基大环
CN111606908B (zh) Jak抑制剂化合物及其用途
CN104125959B (zh) 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂‑吡啶酮化合物
WO2021169990A1 (zh) 用于癌症治疗的kras抑制剂
CN114349750A (zh) Kras突变蛋白抑制剂
TW201713665A (zh) 適用於治療與ｎｔｒｋ相關之病症的化合物及組合物
WO2021115457A9 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN110950876B (zh) 一类呋喃并内酰胺类化合物、制备方法和用途
KR20200044062A (ko) 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
TW202003465A (zh) 作為共價menin抑制劑之六氫吡啶化合物
WO2021180235A1 (zh) Zeste增强子同源物2抑制剂及其用途
EP3632903A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
CN112979655A (zh) 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
WO2022161461A1 (zh) Sos1抑制剂及其制备方法和应用
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
WO2023179600A1 (zh) 新型取代大杂环类新化合物及其应用
CN114805311A (zh) 螺环茚
WO2023151621A1 (zh) 具有抗kras突变肿瘤活性的化合物
KR20230123471A (ko) 화합물, 조성물 및 방법
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
CN113493438A (zh) 四氢异喹啉类化合物
WO2020233645A1 (zh) 大环类衍生物、及其制备方法和用途
WO2020048347A1 (zh) 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant